SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

D MUELLER1, M ALLENSPACH1, A OTHMAN1, C SAELY2, A MUENDLEIN2, A VONBANK2, H DREXEL2, A VON ECKARDSTEIN1

1Institute of Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland, 2Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, 6807 Feldkirch, Austria

After ingestion of phosphatidylcholine, L-carnitine or betaine, trimethylamine-N-oxide (TMAO) is formed by gut microbiota and liver enzymes. Elevated TMAO plasma levels were associated with increased cardiovascular risk and other diseases. Also betaine and choline itself were recently associated with increased cardiovascular risk. A newly developed LC-HRMS method was applied to measure the plasma concentrations of TMAO, betaine and choline in a cohort of 339 patients undergoing coronary angiography for the evaluation of suspected coronary artery disease. Betaine concentrations in males were significantly higher than in females (42.0 vs. 35.9 µmol/L; p<0.001). Plasma concentrations of TMAO but not of betaine or choline were higher in patients with diabetes compared to euglycemic patients (2.39 vs. 0.980 µmol/L; p=0.001) as well as in patients with metabolic syndrome as compared to patients without metabolic syndrome (2.37 vs. 1.43 µmol/L; p=0.002). Plasma concentrations of TMAO or choline increased significantly with decreasing renal function (Spearman’s rho: -0.281; p<0.001, or -0.285; p<0.001). However, plasma levels of TMAO or betaine were not significantly associated with neither a history of myocardial infarction nor the angiographically assessed presence of coronary heart disease, nor incident cardiovascular events during 8 years of follow-up. Plasma levels of TMAO are therefore confounded by impaired kidney function and poor metabolic control. Adjusted for these confounders, TMAO levels were not significantly associated with the history, presence or incidence of symptoms or events of coronary heart disease.

Agenda

07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr

pipette

pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen

Jobs

17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers